BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 ...

Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.

Rhythm Pharma (RYTM) added ~15% on Thursday after the company announced plans to advance its lead asset, setmelanotide, into a registrational Phase 3 trial for a rare genetic disorder called ...

The company said that reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that ...

Vanderbilt University Medical Center is recruiting participants for the Phase 3 Hunger Elimination or Reduction Objective ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

The Boston-based pharmaceutical company said the Phase 2 trial showed that setmelanotide was effective in reducing body mass index and hyperphagia in patients with Prader-Willi syndrome, a genetic ...

According to the Prader-Willi Syndrome Association USA, the condition affects approximately one in every 15,000 live births. The hallmark feature of PWS is hyperphagia-a chronic, life-threatening ...

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with ...

Patients with Prader-Willi syndrome showed early signs of microvascular disease upon screening. In a study using urinalysis screening to detect microvascular disease, 1 in 5 adults with Prader-Willi ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ. The company will ...

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readoutClinical trial sites in Canada and the ...